Published in Cardiovasc Res on November 01, 1992
A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms. Sci Transl Med (2011) 1.78
Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J (1995) 1.14
Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol (2002) 0.98
Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol (1994) 0.83
Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. Br J Pharmacol (1996) 0.80
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. J Mol Cell Cardiol (2015) 0.79
Effects of Na+ channel blockers on the restitution of refractory period, conduction time, and excitation wavelength in perfused guinea-pig heart. PLoS One (2017) 0.75
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation (1995) 4.48
Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett (2000) 2.10
Tetrodotoxin block of sodium channels in rabbit Purkinje fibers. Interactions between toxin binding and channel gating. J Gen Physiol (1981) 2.07
Voltage clamp measurements of sodium channel properties in rabbit cardiac Purkinje fibres. J Physiol (1980) 1.75
Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. An effect on steady state sodium currents? Circ Res (1982) 1.75
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem (1999) 1.65
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology (1996) 1.59
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun (1996) 1.53
Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation (1990) 1.38
Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem (1996) 1.28
Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice. Circ Res (1998) 1.25
Electrical properties associated with wide intercellular clefts in rabbit Purkinje fibres. J Physiol (1979) 1.25
Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol. J Cardiovasc Pharmacol (1992) 1.21
Modulation of the delayed rectifier, IK, by cadmium in cat ventricular myocytes. Am J Physiol (1992) 1.04
Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of IK block and lack of reverse use dependence in cat ventricular myocytes. Cardiovasc Res (1993) 1.03
Effects of external calcium, calcium channel-blocking agents, and stimulation frequency on cycle length-dependent changes in canine cardiac action potential duration. Circ Res (1980) 0.89
(Q)SAR modeling and safety assessment in regulatory review. Clin Pharmacol Ther (2012) 0.87
Leukotriene B4 production and pharmacologic regulation of reverse passive Arthus pleurisy: importance of antigen dose. Agents Actions (1987) 0.86
Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and In vivo bladder instability in rat. J Pharmacol Exp Ther (1999) 0.85
A novel insulin secretagogue is a phosphodiesterase inhibitor. Diabetes (1995) 0.83
Tetrodotoxin block of cardiac sodium channels during repetitive or steady depolarizations in the rabbit [proceedings]. J Physiol (1979) 0.83
What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs. Cardiovasc Res (2003) 0.81
Ion channels: too complex for rational drug design? Neuron (1996) 0.79
Electromechanical effects of the putative potassium channel activator celikalim (WAY-120,491) on feline atrial and ventricular muscle. J Pharmacol Exp Ther (1992) 0.78
SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors. J Pharmacol Exp Ther (1994) 0.76
Antiarrhythmic drug binding sites in cardiac K+ channels. Circ Res (1996) 0.75
Potassium channel activators cromakalim and celikalim (WAY-120,491) fail to decrease myocardial infarct size in the anesthetized canine. Pharmacology (1992) 0.75
Another layer of ventricular heterogeneity? Alpha 1 agonists prolong repolarization in Purkinje fibers but not M-cells. Cardiovasc Res (1999) 0.75
Efficacy of the antidepressant iprindole against experimental arrhythmias. Eur J Pharmacol (1986) 0.75
Potentiation of phosphodiesterase inhibitor antithrombotic activity with alpha-2 adrenergic blockade. Life Sci (1991) 0.75
Electrical properties of canine subendocardial Purkinje fibers surviving in 1-day-old experimental myocardial infarction. Circ Res (1990) 0.75
Cellular electrophysiology of the new antiarrhythmic agent recainam (Wy-42,362) in canine cardiac Purkinje fibers. J Cardiovasc Pharmacol (1987) 0.75
Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone. Thromb Res (1991) 0.75
The effects of the putative potassium channel activator WAY-120,491 on 86Rb efflux from the rabbit aorta. J Pharmacol Exp Ther (1991) 0.75
Analysis of the potassium channel openers celikalim, pinacidil and cromakalim in platelet models of thrombosis. Thromb Res (1994) 0.75